































levels	 of	 FGF21	 in	 rodents	 and	 humans.	 However,	 carbohydrate	 consumption	 also	 results	 in	
secretion	of	insulin.		
Objective:	 The	 aim	 of	 this	 study	 was	 to	 examine	 the	 combined	 and	 independent	 effects	 of	
hyperglycemia	and	hyperinsulinemia	on	total	and	bioactive	FGF21	in	the	postprandial	period	in	

































states,	 FGF21	 is	 elevated	 in	 the	 plasma,	 albeit	 demonstrating	 significant	 inter-individual	
















proteolytic	 cleavage	 of	 the	 C-terminus	 by	 fibroblast	 activation	 protein	 (FAPα),	 a	 serine	
dipeptidase	 and	member	of	 the	 S9	 family	 proteases23.	Numerous	 studies	have	examined	 the	
















or	metformin	 (n	=	5;	dose	1300	±	300	mg/d)	participated.	Patients	were	excluded	 if	 they	were	







prior	 to	 obtaining	written	 informed	 consent.	 All	 procedures	 were	 performed	 according	 to	 the	







































analyzed	 for	 insulin	 concentrations	 by	 radioimmunoassay	 (Diagnostics	 Products	 Corporation,	
Llanberis,	 Wales,	 UK),	 and	 total	 FGF21	 (Biovendor,	 Research	 and	 Diagnostics	 products,	 Czech	































FGF21	 responded	differently	 over	 time	 (P	 <	 0.05)	with	 a	 significant	 increase	 observed	 in	 the	
control	subjects	that	was	impaired	in	patients	with	T2D	(Fig	2C).	In	line	with	the	lower	ratio	of	
bioactive	 to	 total	 FGF21,	 circulating	 FAPa	 concentrations	 remained	 higher	 (P	 <	 0.05)	 in	 T2D	
subjects	throughout	the	OGTT	(Fig	2D).	Thus,	here	we	report	that	the	normal	postprandial	rise	in	
the	ratio	of	bioactive	to	total	FGF21	is	attenuated	in	T2D	patients	and	this	effect	is	associated	
with	 both	 reduced	postprandial	 insulin	 concentrations	 and	 increased	 circulating	 levels	 of	 the	




To	 determine	 directly	 whether	 glucose	 and/or	 insulin	 account	 for	 the	 postprandial	 rise	 in	
circulating	 FGF21	 following	dextrose	 consumption,	we	assessed	 FGF21	 in	blood	 from	healthy	
volunteers	 collected	 during	 4	 h	 of	 HIHG,	 HIEG	 and	 EIHG	 clamps.	 The	 magnitude	 of	










in	 total	 and	 bioactive	 FGF21	 that	 occurs	 following	 dextrose	 ingestion	 is	 facilitated	 by	 the	
corresponding	increase	in	circulating	insulin	levels.		
Insulin-mediated	secretion	of	FGF21	is	impaired	following	high	fat	feeding	
Short-term	 HF	 in	 humans	 has	 been	 shown	 to	 alter	 inulin-stimulated	 substrate	 utilization	 in	

























total	 and	 bioactive).	 This	 effect	 is	 lost	 in	 the	 euinsulinemic-hyperglycemic	 clamp.	 These	 data	
suggest	 the	 rise	 in	 total	 and	 bioactive	 FGF21	 that	 occurs	 following	 dextrose	 ingestion	 is	 a	
consequence	 of	 the	 increase	 in	 insulin	 secretion.	 Finally,	 in	 response	 to	 a	 high	 fat	 dietary	







































insulin	 sensitivity	 in	 diet-induced	 obese	mice	 where	 total	 and	 bioactive	 plasma	 FGF21	 were	
observed	 to	 be	 elevated.	 Interestingly,	 these	 effects	 were	 attenuated	 in	 FGF21	 knockout	
animals38.	TB	was	previously	pursued	as	an	anti-cancer	treatment	and	was	found	to	be	safe	to	
support	 repeated	 dosing	 in	 human	 clinical	 trials39.	Whilst	 TB	 is	 not	 selective	 to	 FAP,	 further	
studies	 in	 humans	 are	 required	 to	 evaluate	 the	 use	 of	 FAP	 inhibitors	 as	 relevant	 treatment	
strategy	in	T2D	patients,	particularly	as	FGF21	improves	MetS	in	humans1,40.	
In	summary,	we	employed	a	physiological	and	dietary	strategy	in	human	subjects	which	revealed	
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